Life science Company focusing on stem cell-based therapies, BioRestorative Therapies (OTCMKTS:BRTX) on September 2, 2021, announced that the Australian Patent Office issued a patent pertaining to the metabolic ThermoStem Program.
Claims under the fresh patent include implantable scaffold as well as brown adipocytes from brown adipose of human-derived stem cells besides methods of use. A type of fat tissue in humans, Brown adipocytes regulates metabolic activity. The initial preclinical research demonstrates surge in brown fat in animals may be the cause of more caloric burning in addition to lower glucose and lipid levels. Researchers have seen that people with more amount of brown fat will have a lower risk for diabetes and obesity.
Lance Alstodt, the Company’s CEO said that the claims given under the patent are important as they are pertaining to implantable scaffolds as well as methods of use in patients suffering from metabolic disorders. Alstodt added that the firm will continue developing the ThermoStem program and it is vital on developing methods of delivery.
BioRestorative Therapies develops therapeutic products harnessing tissue and cell protocols, especially engaging adult stem cells. The firm’s two key programs are related to metabolic diseases well as the treatment of disc/spine disease.